A Phase 1, Open-Label Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment

Inclusion Criteria: * Ability to comprehend and willingness to sign a written ICF for the study. * Aged 18 to 80 years, inclusive, at the time of signing the ICF. * Moderate or severe hepatic impairment based on CP score. * Medical findings consistent with the degree of hepatic dysfunction, determined by medical history, physical examination, vital sign measurements, 12-lead ECGs, and clinical laboratory determinations at screening or check-in (as applicable). Participants with abnormal findings considered not clinically significant by the medical monitor or investigator are eligible. * Body…